/
EQ
$3.08+$0.03 (+0.98%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$192.8M
63M shares
52-week range
$0.29 – $3.45
88% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
5.77%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-2.70
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $15.8M | $36.1M | $41.1M | $0 |
| Cost of revenue | $6.1K | $23.0K | $45.0K | $0 | $0 | $0 | $0 | $116.0K |
| Gross profit | −$6.1K | −$23.0K | −$45.0K | $0 | $15.8M | $36.1M | $41.1M | −$116.0K |
| Gross margin | — | — | — | — | 100.0% | 100.0% | 100.0% | — |
| R&D | $4.9M | $17.6M | $19.4M | $26.4M | $37.5M | $37.0M | $37.4M | $12.8M |
| Operating income | −$8.6M | −$26.7M | −$29.5M | −$37.8M | −$62.1M | −$14.5M | −$8.3M | −$23.6M |
| EBITDA | −$10.7M | −$25.3M | −$28.7M | −$37.9M | −$61.3M | −$12.1M | −$7.6M | −$22.3M |
| Net income | −$13.3M | −$25.6M | −$29.8M | −$39.0M | −$62.4M | −$13.3M | −$8.1M | −$22.4M |
| Net margin | — | — | — | — | -396.1% | -37.0% | -19.6% | — |
| EPS (diluted) | -1.09 | -1.47 | -1.46 | -1.35 | -3.19 | -0.38 | -0.23 | -0.39 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $16M | $-0.23 | $-0.30–$-0.18 | 6 |
| 2027 | $17M | $-0.25 | $-0.34–$-0.21 | 6 |
| 2028 | $52M | $-0.29 | $-0.44–$-0.22 | 7 |
| 2029 | $89M | $-0.33 | $-0.33–$-0.33 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.32
Price
$3.08
Implied downside
-90%
Peer comparison
Equillium, Inc. Common Stock
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.
www.equilliumbio.com- Employees
- 14
- IPO / List date
- Oct 12, 2018
- HQ
- LA JOLLA, CA
Held by traders on TradeandTell
No one on the platform currently holds EQ.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 656,964 | $1.3M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded EQ yet.
